USA - engelsk - NLM (National Library of Medicine)

bayer healthcare llc animal health division - enrofloxacin (unii: 3dx3xek1bn) (enrofloxacin - unii:3dx3xek1bn) - enrofloxacin 22.7 mg - baytril® (brand of enrofloxacin)taste tabs® antibacterial tablets are indicated for the management of diseases associated with bacteria susceptible to enrofloxacin. baytril antibacterial tablets are indicated for use in dogs and cats. enrofloxacin is contraindicated in dogs and cats known to be hypersensitive to quinolones. dogs: based on the studies discussed under the section on animal safety summary, the use of enrofloxacin is contraindicated in small and medium breeds of dogs during the rapid growth phase (between 2 and 8 months of age). the safe use of enrofloxacin has not been established in large and giant breeds during the rapid growth phase. large breeds may be in this phase for up to one year of age and the giant breeds for up to 18 months. in clinical field trials utilizing a daily oral dose of 5.0 mg/kg, there were no reports of lameness or joint problems in any breed. however, controlled studies with histological examination of the articular cartilage have not been conducted in the large or gia

Kina - kinesisk - CFDA (药监局 - 中国食品和药物管理局)

bayer healthcare llc - 注射剂 - 500iu/瓶

Kina - kinesisk - CFDA (药监局 - 中国食品和药物管理局)

bayer healthcare llc - 注射剂 - 250iu/瓶

Kina - kinesisk - CFDA (药监局 - 中国食品和药物管理局)

bayer healthcare llc - 注射剂 - 1000iu/瓶

Cuba - spansk - CECMED (Autoridad Reguladora de Medicamentos, Equipos y Dispositivos Médicos)

bayer healthcare llc. - factor antihemofílico recombinante (rfviii), octogoc alfa) - polvo liofilizado para solución inyectable - 500 ui

Cuba - spansk - CECMED (Autoridad Reguladora de Medicamentos, Equipos y Dispositivos Médicos)

bayer healthcare llc. - factor antihemofílico recombinante (rfviii), octogoc alfa) - polvo liofilizado para solución inyectable - 250 ui

Cuba - spansk - CECMED (Autoridad Reguladora de Medicamentos, Equipos y Dispositivos Médicos)

bayer healthcare llc. - factor antihemofílico recombinante (rfviii), octogoc alfa) - polvo liofilizado para solución inyectable - 1000 ui

New Zealand - engelsk - Medsafe (Medicines Safety Authority)

bayer new zealand limited - octocog alfa 1000 [iu] - injection with diluent - 1000 iu - active: octocog alfa 1000 [iu] excipient: calcium chloride dihydrate glycine histidine polysorbate 80 sodium chloride sucrose water for injection water for injection - kogenate fs is indicated in congenital factor viii deficiency (haemophilia a) for the treatment and prophylaxis of bleeding in untreated and previously treated patients without inhibitors.

New Zealand - engelsk - Medsafe (Medicines Safety Authority)

bayer new zealand limited - octocog alfa 2000 [iu] (recombinant factor viii) - injection with diluent - 2000 iu - active: octocog alfa 2000 [iu] (recombinant factor viii) excipient: calcium chloride glycine histidine polysorbate 80 sodium chloride sucrose water for injection water for injection - kogenate fs is indicated in congenital factor viii deficiency (haemophilia a) for the treatment and prophylaxis of bleeding in untreated and previously treated patients without inhibitors.

New Zealand - engelsk - Medsafe (Medicines Safety Authority)

bayer new zealand limited - octocog alfa 250 [iu] - injection with diluent - 250 iu - active: octocog alfa 250 [iu] excipient: calcium chloride dihydrate glycine histidine polysorbate 80 sodium chloride sucrose water for injection water for injection - kogenate fs is indicated in congenital factor viii deficiency (haemophilia a) for the treatment and prophylaxis of bleeding in untreated and previously treated patients without inhibitors.